Optimizing Antiplatelet Therapy in Cardiogenic SHOCK-Cangrelor in AMI & CS

Video Transcription

Video Summary

The speaker, an interventional cardiologist, reviews recent data on cangrelor use in acute myocardial infarction (AMI) and cardiogenic shock. The CAMEO registry's findings highlight cangrelor's advantages, especially during PCI procedures where oral P2Y12 inhibitors may be ineffective due to conditions like poor gut absorption. Cangrelor shows efficacy without significantly increasing bleeding risks in AMI and cardiogenic shock patients. The study also investigates cangrelor's use in patients undergoing CABG, showing variable practice patterns. The key takeaway emphasizes the variability of cangrelor application based on the institutions and patient conditions.

Asset Subtitle

Jennifer Rymer, MD, MBA, MHS

Keywords

cangrelor

acute myocardial infarction

cardiogenic shock

CAMEO registry

PCI procedures